News
Q1 revenues increased 412% year over year, driven by AI Nose productsDelivers strong turnaround from gross loss to gross profit in Q1AI Nose gains traction beyond healthcare with strategic ...
Q1 revenues increased 412% year over year, driven by AI Nose productsDelivers strong turnaround from gross loss to gross profit in Q1AI Nose gains traction beyond healthcare with strategic partnership ...
Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback